Armed with promising alopecia PhII, Concert edges forward with modified JAK inhibitor — but safety will still be key
Concert Pharma has scored a fresh round of positive Phase II data for its JAK inhibitor amid an ongoing rivalry with Pfizer, paving the way for a late-stage showdown in alopecia areata. It’s also cautiously staking a claim about safety at a time the whole class is under a cloud of uncertainty.
The glowing results — in which both the 8 mg and 12 mg twice-daily doses of CTP-543 hit the primary endpoint of relieving hair loss — recouped some enthusiasm for the drug lost in its interim readout. Investigators reported that 58% of patients in the 12 mg cohort achieved at least 50% relative reduction in the overall Severity of Alopecia Tool (SALT) while 47% in the 8 mg group saw that improvement, compared to 9% for placebo (p <0.001 in both cases).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.